DURHAM, N.C. SEPTEMBER 05, 2019 - Results of a phase II clinical trial released today in STEM CELLS Translational Medicine (SCTM) indicate that a limbal stem cell (LSC) transplantation is superior to a tissue graft in treating limbal stem cell deficiency syndrome (LSCD).
You are here
Press Releases from AlphaMed Press
September 6, 2019
August 14, 2019
DURHAM, N.C. AUGUST 14, 2019 - A study released today in STEM CELLS Translational Medicine provides compelling evidence of how an injection of human amniotic fluid stem cells can be used to protect the spinal cord of a fetus from myelomeningocele (MMC). The finding could lead to a new strategy for treating this debilitating birth defect that affects about 1 out of every 4,000 children born in the United States each year.
The most severe form of spina bifida, myelomeningocele results when the backbone and spinal canal do not close before birth. It can leave a child with many disabilities, including partial or full paralysis, difficulty with bowel and bladder control, hydrocephalus and developmental delay.
August 6, 2019
Durham, NC – A study released today in STEM CELLS Translational Medicine (SCTM) identifies a computational modeling system that could have far-reaching implications for personalized medicine, especially when seeking treatments for children with heart failure. The system, called partial least squares regression (PLSR), is able to predict which stem cell donors and manipulation methods might yield the best therapies for these patients.
June 26, 2019
DURHAM, N.C. (JUNE 26, 2019) - Results of a phase 1 clinical trial released today in STEM CELLS Translational Medicine (SCTM) have identified a specific line of human neural stem cells that shows potential for helping recover motor function in those who suffer a hemiparetic stroke (where one side of the body is left weak or paralyzed).
June 25, 2019
DURHAM, N.C. (JUNE 25, 2019) - A study released today in STEM CELLS identifies a possible new way to regrow hair. The research demonstrates how extracellular vesicles (EVs), isolated from stimulated dermal fibroblasts, promote hair growth via their secretion of the protein norrin — and how norrin is a key player in growing hair.
The discovery could lead to numerous therapeutic treatments for alopecia (hair loss), the researchers say.
June 20, 2019
DURHAM, N.C. ( JUNE 20, 2019 ) - A study released today in STEM CELLS Translational Medicine (SCTM) demonstrates how preconditioning mesenchymal stem cells (MSCs) enhances their ability to treat acute respiratory distress disorder (ARDS). This important information could point to a way to developing more effective MSC treatments for clinical application, according to Ben Antebi, Ph.D., who led the team of investigators from the U.S. Army Institute of Surgical Research and Stanford University.
June 11, 2019
DURHAM, N.C. JUNE 11, 2019 - A study released today in STEM CELLS demonstrates how extracellular vesicles derived from human mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ cells, modifying their gene expression and increasing their viability and cloning ability. In a test on mice, MSC-EVs also increased the cells’ ability to lodge into bone marrow. This research performed by Prof. Sanchez-Guijo’s Lab at the IBSAL-University of Salamanca (Spain) could potentially overcome serious complications due to graft failure or poor engraftment from allogeneic stem cell transplantation.
June 1, 2019
DURHAM, N.C. (MAY 30, 2019) - A study released today in STEM CELLS Translational Medicine is the first to demonstrate an efficient delivery system for the sustained release of human placental stem cell (HPSC)-derived conditioned medium (CM) to treat acute kidney injuries. The platelet-rich plasma-based gel system was able to deliver CM into the injured kidney, where it helped restore function and regenerate injured tissue.
May 14, 2019
DURHAM, N.C. (MAY 14, 2019) - A study recently published in STEM CELLS shows a new method for accelerating human pluripotent stem cell-derived cardiomyocytes’ (hPSC-CMs) development. If a way can be found to overcome hPSC-CMs’ developmental immaturity, which leaves them functionally and structurally different from mature human cardiomyocytes, they can be powerful tools for disease modeling, drug development, basic research and new therapies. This study shows great promise in resolving this issue.
April 11, 2019
DURHAM, N.C. (APRIL 11, 2019) - A study released today in STEM CELLS shows how a new class of cancer drugs, called Smac mimetics, is effective in killing off the stem cells that lead to glioblastoma (GBM) depending on oxygen level. This might help pave the way to a new, more efficient method for treating the most common and aggressive form of brain cancer in adults.
